{"version":"1.0","type":"link","title":"First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial.","author_name":"Zhang F 외","author_url":"https://prs-insight.online/author/Zhang%20F","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/97582","thumbnail_width":1200,"thumbnail_height":630}